|
Pulmotect’s management team includes AlphaDev, LLC as well
as the lead inventors and founders of the technology. In
collaboration with leading institutions, this team is well
positioned to achieve the immediate milestones transitioning
our products into the clinic.
|
Burton Dickey, MD |
Burton Dickey, MD, is the Chair of the Pulmonary
Department at the University of Texas M. D. Anderson
Cancer Center. He is an inventor of a first
generation technology and co-founder of Pulmotect.
An experienced bench investigator, he has served on
multiple NIH study sections. An active clinician, he
participates in several clinical research programs
and serves on the advisory board of multiple
companies. |
|
Magnus Höök, PhD |
Magnus Höök, PhD, is a Regents Professor, Institute
of Biosciences and Technology at Texas A&M. He is
the Director of the Center for Extracellular Matrix
Biology, was recognized in 2005 as one of the top 5%
funded scientist from the NIH for the past 25 years;
is an inventor of the peptide and co-founder of
Pulmotect. He is also a co-founder of Inhibitex,
Inc., a publicly traded company. He has served on
scientific advisory boards of several companies. |
|
Brenton Scott, PhD,
MBA |
Brenton Scott, PhD, MBA, co-founder of Pulmotect and
AlphaDev, LLC Senior Associate. He has served as an
NSF reviewer on SBIR grants. His graduate and
postgraduate experience focused on vesicular
traffic, airway inflammation and infection. He
received his PhD in Biochemistry and Cell Biology
from Rice University and his MBA from University of
Houston.
|
|
 |
AlphaDev, LLC is a Houston-based development company
that exists to turn early-stage life science
technologies into medical companies and products.
AlphaDev employs a low management burn model that
optimizes flexibility and partnerships, brings
proven management and strategic judgment to build
start-ups into successful companies and manages the
development process through important milestones
toward commercial exits, including bringing in
stand-alone management and new investors.
|
“Our
findings not only have implications for guarding cancer
patients against infection, but they also potentially offer
the general public protection against both biological
weapons and respiratory epidemics.” Dr. Burton Dickey
|
|
